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Reversed Chloroquine Molecules as a Strategy to Overcome Resistance in
Malaria
David H. Peyton*
Department of Chemistry, Portland State University, Portland, OR 97207-0751
Abstract: This short review tells the story of how Reversed Chloroquine drugs (RCQs) were developed. These are hybrid
molecules, made by combining the quinoline nucleus from chloroquine (CQ) with moieties which are designed to inhibit
efflux via known transporters in the membrane of the digestive vacuole of the malaria parasite. The resulting RCQ drugs
can have potencies exceeding that of CQ, while at the same time having physical chemical characteristics that may make
them favorable as partner drugs in combination therapies. The need for such novel antimalarial drugs will continue for the
foreseeable future.

Keywords: Antimalarial, chloroquine, Plasmodium falciparum, drug development, drug design, structure activity relationship,
malaria, drug resistance.
INTRODUCTION
Chloroquine (CQ) was a truly remarkable drug, and the
standard of care for malaria over about half a century, beginning in the late 1940s. Speaking about the discovery of CQ
in a Review Lecture published in 1963, G. Robert Coatney
stated [1], “Results since 1946 have made it the drug of
choice for malaria the world over. It was the only antimalarial used by our Armed Forces and most of the Allied Forces
in Korea. It has since been employed by most of the Free
World Forces when deployed in malarious areas and is the
drug of choice in the world-wide malaria eradication program under the World Health Organization.”
Of course, that worldwide malaria eradication program
did not succeed, and upon its abandonment the situation regarding malaria grew worse. The emergence and subsequent
spread of drug resistance in malaria had made the (otherwise
favored) malaria drug CQ ineffective throughout most of the
world [2]. Combination therapies [3, 4] have now become
the standard of care for malaria chemotherapy, though currently available combinations lack CQ’s simplicity & low
cost. Because malaria will doubtless continue to evolve resistance even to the newest cures [5, 6], there is, and will be
an ongoing need for a development pipeline of effective
drugs until eradication of the disease might become a reality.
In response to this challenging situation, we embarked
upon a hybrid-drug approach to overcoming malaria’s drug
resistance. Chemosensitizers, or reversal agents (RAs), are
molecules that reverse resistance to a drug. In the context of
this review, the RA is generally an efflux mechanism inhibitor. RAs for CQ turn the susceptibility of CQ-resistant
strains back toward that of CQ-sensitive strains [7-11],
mainly by inhibiting the transporter of CQ from the digestive
vacuole (DV) – P. falciparum chloroquine-resistance transporter (PfCRT) [12]. We originally hypothesized and
*Address correspondence to this author at the Department of Chemistry,
Portland State University, Portland, OR 97207-0751; Tel: 503 725-3875;
Fax: 503 725-3888; E-mail: peytond@pdx.edu
1-2/12 $58.00+.00

showed that CQ-resistance could be reversed by covalently
bonding CQ to a RA, producing a single molecule that we
term a ‘reversed-CQ’ (RCQ) compound [13]; this is illustrated in Fig. (1). An RCQ compound has a significant advantage over a cocktail of CQ and RA because CQ accumulates strongly in the parasite’s DV, so the linked RA entity
accumulates to a much higher concentration than an unlinked
RA. The drug:RA ratio is, by definition, 1:1. We have demonstrated the feasibility of this approach by making several
dozens of these compounds, and shown that the design is
robust and flexible [13-15]. We have generated a large number of potent and novel RCQ compounds that are very effective against both CQ-sensitive and CQ-resistant strains at
concentrations far lower than CQ or other similar drugs. In
vitro cytotoxicity results for these drugs are favorable [14,
15]. In fact, with the better RCQ drugs we have not observed
any adverse effects in mice when the drugs are administered
orally with an amount well over an order of magnitude above
the in vivo ED50 values, and well above the fatal CQ dose.
What follows is a short story about how the RCQ molecules have developed in our laboratory, and a brief description of a few molecule classes that are closely related to the
RCQ design. The reader can refer to other publications for
reviews covering fundamentals of malaria’s CQ-resistance
[16], the discovery and development of resistance reversal
drugs [10, 17], hybrid drugs for malaria [18], as well as hybrid drugs generally [19, 20], in addition to a recent review
covering the need for new malaria drugs [21].
THE “TARGET”: PfCRT
A protein localized to the membrane defining the digestive vacuole (DV) of P. falciparum was discovered by the
Wellems group at NIH to have mutations that are correlated
to CQ-resistance [12]. Since the function of this protein was
not known, it was designated as the, “P. falciparum Chloroquine Resistance Transporter,” or PfCRT. Although there
were multiple mutations found within the locus of the pfcrt
gene, a key mutation for CQ-resistance was K76T. Most
© 2012 Bentham Science Publishers
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Fig. (1). The original concept leading to RCQ drugs. Note the chiral center in CQ that we eliminate in a RCQ drug.

importantly, incorporation of this mutation into a CQsensitive strain induced the CQ-resistance trait. This, and
several quickly following papers, e.g., [22-25] established
the importance of this point mutation in P. falciparum CQresistance, although other mutations and probably other
transporters are known to modulate the trait [16, 22, 25-27].
The structure of PfCRT has been predicted to contain 10
transmembrane helices, with the N- and C- termini extending
into the parasite’s cytoplasm, away from the DV [12]. The
K76T location is near at the proposed DV-end of the
N-terminal (first) transmembrane helix, and so could interact
electrostatically with drugs like CQ, which exists as the dication when in the acidic DV; the loss of the positivelycharged lysine residue could then form the basis for resistance by reducing this unfavorable interaction such that the
drug then can bind and be transported. In any event, the
thermodynamics involved in the transport process are not
simple, as recently reviewed [27].
THE FIRST RCQ MOLECULE
The fundamental design of a reversed drug molecule is a
hybridization of the original drug with a reversal agent
(chemosentizer) that can inhibit the resistance mechanism, in
this case the export of the drug by an efflux mechanism. For
our initial RCQ drug, we chose a reversal agent moiety that
was known to produce a buildup of CQ (pKa ~ 8.1 & 10.2
[28]) within the parasite (and so presumably in the DV; pH ~
5 [28]). Such molecules, including verapamil (VP), are often
thought of by their activities as calcium channel blockers.
Although VP was the usual reference for a CQ-resistance
reversal agent, it is somewhat complex from a chemical perspective. However a simpler choice, imipramine (pKa ~ 9.5
[29]), was also known to be a potent RA [11, 30-32], and is
achiral, unlike VP and many other reversal agents known to
act against CQ-resistance. The commercial availability of
desimipramine led to a simple synthesis for the molecule, 1,
also achiral and first published in 2006 [13]. The structure
and synthetic route are shown in Fig. (2). This molecule, to
our knowledge, was the first reported hybrid drug that intentionally incorporated a chemical-efflux inhibitor coupled to a
drug molecule. When tested in vitro against both a CQsensitive P. falciparum strain (D6) and against a CQresistant strain (Dd2), using the SYBR Green I-based fluorescence assay [33], it was found to be more potent than CQ
against either strain, even the CQ-sensitive strain. However,

RCQ molecule 1 has a very high estimated clogP of nearly 9,
as well as a clogD of 4.2 at pH 7.4 (Marvin 5.5.0.0, 2011,
ChemAxon (http://www.chemaxon.com) was used for this
calculation), and so was not expected to be a practical drug
itself. Nonetheless, we evaluated the in vivo potential of the
RCQ drugs in a small mouse trial using P. chabaudi, and
found that 1 had >99% suppressive activity at 64 mg/kg/day
in a standard 4-day suppressive test. It is important, however,
to remember that 1 was a prototype molecule, assembled to
test the principle without being optimized. We then returned
to the principles of the RA pharmacophore to begin the optimization process.
SECOND-GENERATION RCQ MOLECULES
The structural essentials for the CQ-resistance reversing
RA molecules identified by Bhattacharjee et al. in 2002 [34]
included, “Two aromatic hydrophobic sites and a hydrogen
bond acceptor site, preferably at a side chain nitrogen atom.
We took this conclusion, based on a modeling / calculation
approach based on a training set of 17 compounds, as license
to open up the RA structure to modifications in a guided way
that would remove the tricyclic nature of the imipraminebased RA end of molecule 1. This might reduce or eliminate
any central neural system (CNS) activity of the resultant
drugs. In addition, there were the questions of watersolubility and oral availability of the drug to address.
We began to evaluate the structural requirements for an
RCQ drug by examining the limits to which one could practically vary the “linker” between the quinoline and the RA’s
side-chain nitrogen, as well as between that nitrogen and the
RA aromatic rings [14]. We found little differences between
RCQ molecules that had between 2 and 4 carbons in the
linker between the quinoline and the RA’s side-chain nitrogen, and significant changes could be made to the RA structures themselves. A few examples are shown in Table 1. The
length of the chain between the nitrogen and the 2 aromatic
groups was varied between 2 and 4 carbons (and changed to
a piperazinyl ring) with little change in activity, as well as
incorporating a carbonyl (but not converting the central nitrogen into an amide). The aromatic rings were converted
from phenyls to benzyls, with little change in activity. A
recent paper addresses the ability of this moiety to act specifically as an inhibitor of mutated PfCRT [35]. Two other
points that arose from this structure-activity relationship
(SAR) work were that having a proton on the quinoline’s
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Fig. (2). The synthesis and structure of prototype RCQ molecule, 1 [13]. The hydrogen-bond accepting nitrogen is indicated with an arrow, and the reversal agent aromatic groups are circled; the RA moiety will be shown in bold bonds throughout. In the structure of 1, the quinoline and linker are contained in the line-box, and the RA moiety is in the dotted box.

Table 1.

Selected RCQ Activities against P. falciparum [14]
IC50 b (nM)
Compound



ClogP a

D6
(CQS)

Dd2
(CQR)

IC50 Ratio
Dd2/D6

Cytotoxicity c
(nM)

CQ

5.1

7

102

15

12000

1

8.9

3

5

1.7

700

2

3.5

1.6

1.8

1.1

6500

3

7.5

1.3

1.3

1.0

1100
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(Table 1) contd….
IC50 b (nM)
Compound

a
b

ClogP

a

D6
(CQS)

Dd2
(CQR)

IC50 Ratio
Dd2/D6

Cytotoxicity c
(nM)

4

7.0

10

16

1.6

2200

5

7.3

7

16

2.3

N.D.

6

7.3

2

6

3.0

N.D.

7

7.6

23

34

1.5

700

8

7.4

8

11

1.4

1300

Evaluated using ChemDraw software.
Averages of at least 3 runs (± 15%). The uncertainties are estimated based on weighing uncertainties for the various compounds (which are free-bases and often oils), as well as on

variability between determinations that were performed on different weeks.
c

Cytotoxicities are against mouse spleen lymphocytes. These values are estimated to be ±50%, based on weighing uncertainties for the various compounds (which are free-bases and

often oils), as well as on variability between determinations that were performed on different weeks. N.D.: not determined.

4-amino was beneficial, and that having two RA groups was
not a strong advantage. So there was great breadth in scope
found for RCQ design, and considerations such as pharmacology and cost could then be addressed with few constraints. In fact, the latitude for RCQ design appeared to be
much greater than for developing a ‘simple’ RA.
This conclusion underscores the point that there are fundamental differences in the requirements for the design of an
effective RA drug, as opposed to RCQ drugs. First, the RCQ
molecule’s fundamental activity must be antimalarial activity. The functional requirement of a RA molecule is the ability to inhibit efflux of CQ in a malaria strain; the function of
a RA moiety in a RCQ drug is to enhance buildup of the
drug in the DV (presumably by decreasing efflux of itself).
This latter property does not necessarily require that it be
able to inhibit efflux of CQ. In fact, it may be that the best

RCQ drugs may not interact with an efflux effector such as
PfCRT at all: RCQ drugs could bind other transporters in the
DV, or they could simply have lower binding to all such
transporters. This is because binding is the first step in transport, so that reduced binding could lead to a higher RCQ
drug concentration in the DV, even though it would be a less
effective RA for CQ export. Therefore, it may be easier to
design an optimized RCQ drug RA than it would be to design the corresponding RA moiety.
AN IMPROVED RCQ MOLECULE
We continued the SAR work, taking advantage of the
above-referenced flexibility to find a molecule, 2, that has
great water solubility, has good in vitro antimalarial activity
against a variety of CQ-resistant and CQ-sensitive P. falciparum strains, and is orally curative in mice. Its IC50 values
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against D6, Dd2, and 7G8 were about 1, 2, and 2 nM, as
compared to CQ values of 7, 102, and 106 nM. Having a
clogP value of about 3.5 (CQ has a value of about 5), 2 was
anticipated to have good water solubility, especially as a salt
formulation (e.g., chloride or phosphate). Low cytotoxicity
values (in our studies, to mouse spleen lymphocytes), and
the resulting favorable therapeutic index values were found
for many RCQ molecules. For example, the therapeutic index values for CQ and 2 were found to be about 120 and
4000, respectively (ratio of IC50 for mouse spleen lymphocytes / P. falciparum strain Dd2). In vivo work in mice found
that 2 could cure mice of a P. berghei infection at an equimolar dose to 30 mg/kg/day for CQ. Remarkably, while CQ
kills at < 200 mg/kg in mice, we could orally dose 2 to > 400
mg/kg in mice without evident adverse effects for at least 3
days (unpublished).
MECHANISM(S) OF ACTION
While the full story about the mode(s) of action for CQ is
not certain, it has been widely assumed to involve interaction
with heme, a byproduct of hemoglobin digestion by the
Plasmodium parasite. We therefore evaluated the binding of
heme by both CQ and 1 using UV-vis spectroscopy. A binding stoichiometry of one drug molecule to one heme μ-oxo
dimer was assumed. At pH 5.7, near the DV pH, the measured binding constant (3  105 M-1) was found to be the same
as measured for CQ (3  105 M-1). The measured binding
constant at pH 7 (also 3  105 M-1) was also found to be
comparable to that which we measured for CQ (1  106 M-1 )
under the same conditions. The conclusion is that the RA
portion of 1 does not appear to affect the CQ-like binding to
heme. This conclusion has been supported by a recent study
[36]. Compound 2 Fig. (3) also proved to be an avid molecule for the heme μ-oxo dimer, and was about 3-fold more
efficient at inhibiting -hematin formation as Compound 1.
This may indicate that the high potencies of the drugs is a
combination of both enhanced accumulation and enhanced
interaction with heme, both relative to CQ. We also tested
the ability to accumulate in P. falciparum-parasitized red
cells. In this test, compound 1 did, in fact, accumulate to a
stronger degree than did CQ, as measured by the drop of
drug concentration in the surrounding medium. Light microscopic analysis of surviving parasites in high concentrations
of 1 showed a strongly swelled DV, as well as very little
apparent hemozoin crystals. CQ under the same conditions

HN

N

We found that the RCQ drugs’ effectiveness is not due to
varying the length of the linker between the quinoline and
the central nitrogen; this result is important because others
have found that such changes alone can overcome CQresistance. Thus, we synthesized a compound 3 Fig. (3),
which was found to have better antimalarial activity than
CQ, and in combination with the work cited above, we concluded that the ability of the RCQ molecules to overcome
CQ-resistance by the addition of a RA head group to the 4aminoquinoline ring is, in fact, independent of the chain
length between them, at least if the chain length is between 2
and 4 carbons.
The question of whether the RCQ molecules actually
inhibit PfCRT’s ability to export CQ in strains which are
CQ-resistant may best be evaluated by measurement systems
such as implemented by Martin and Kirk [28, 35]. In fact,
molecules such as 1 and 2 do inhibit this ability to inhibit CQ
transport by PfCRT76T (unpublished data).
RELATED MOLECULES
October et al. used the chemistry of 3,4Dihydropyrimidin-2(1H)-ones to construct RCQ molecules
[37]; Fig. (4). Although such molecules lack the protonatable
nitrogen of the classical pharmacophore, this structure did
exhibit excellent potency against CQ-sensitive and CQresistant malaria strains. Another set of molecules, linking
astemizole to the CQ quinoline end likewise proved hopeful
[38]. Substitution of adamantyl groups for the phenyls in the
RA pharmacophore has proved somewhat successful for
others [39] in overcoming P. falciparum resistance, as well
in our laboratory (unpublished). Screening led to related
structures, e.g., [40, 41]. The acridine skeleton has been hybridized to CQ to make related RCQ structures [42]. The
dibemethin group was appended to quinolines to make related hybrids [43], based on this group’s ability to inhibit
PfCRT-mediated efflux of CQ [35], as outlined above. The
drug candidate ferroquine [44, 45] may owe much of its potency to the ability to accumulate in the DV and not be exported by mutated PfCRT.

N

N
N
H

Cl

showed the same qualitative effects, but to a lesser extent.
All this is consistent with an inhibition of hemozoin formation mechanism for the RCQ molecules, in analogy with the
accepted mechanism of CQ, except that the RCQ molecule is
generally more potent across the range of effects.

N
N

HN
N

2

3
Cl

N

Fig. (3). Two additional key RCQ molecules [15]. RCQ drug 2 has good water solubility and oral efficacy, and RCQ 3 has the same linker
length between the 4-amino group and the next nitrogen as does CQ. Both have high potencies against CQ-sensitive and CQ-resistant P.
falciparum strains.
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Fig. (4). Examples of other molecules may be viewed as sharing aspects of RCQ drugs.

Even some older work, eg., bisquinolines; Fig. (4) [46,
47], including piperaquine [48], make up an interesting set of
compounds which may be viewed as potential RCQ molecules, especially if nitrogen atoms are used in the segment
that links the quinolines. The approved drug, piperaquine
makes an interesting case. Fig. (4) shows the essential elements of the RA moiety superimposed on both imipramine
and one end of a piperaquine molecule. In fact, one can almost think of CQ itself as a RA pharmacophore, in that the
molecule can roughly fit the essential structural elements.
Also, binding to PfCRT, a requisite for transport is a trait
shared by RA molecules. In fact, PfCRT (mutated or not)
may be able to transport some or all of the RA molecules, to
various extents [49].

NEXT-GENERATION RCQ MOLECULES
Future efforts in designing RCQ molecules will be aimed
in two directions. First, we are attempting to vary the RA
end to a greater extent, with the idea that it may not be necessary to retain strong binding to PfCRT. The other direction
will be to vary the substituent pattern on the quinoline ring
system, as has been done for CQ-like structures by others,
e.g., [50]. Both of these directions may help to reduce the
hERG binding which gives rise to the potential cardiotoxicity common to quinoline-based malaria drugs [51]. We already have some evidence that the effects of changing the
substituents are not the same as found in CQ and its derivatives.
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THE

One could ask why would we wish to develop new 4aminoquinoline drugs against malaria, especially in the face
of the failure of CQ? The first reason is that the drugs are
generally inexpensive to produce, particularly on a large
scale. The starting materials are not exotic, and the chemistry
required to assemble the molecules is quite safe and simple
[13-15]. Second, the RCQ molecules are a fairly strong departure from the side chain of CQ, so that there may be
minimal cross-resistance to other strains. In fact, we have
evaluated several “field-isolated” strain clones developed
from infected patients, and found no significant resistance to
any of several of the RCQ drugs. Third, the design is exceedingly flexible. This is important because if resistance does
emerge against one drug, then it is possible that a nextgeneration RCQ could take its place. Forth, the physicalchemical properties can be chosen such that its pharmacokinetic parameters would be a good match for another drug in
combination therapy, and such ability could be very useful
for optimizing drug combinations. Finally, CQ was really a
very good drug for nearly half a century. If we are successful
in developing RCQ drugs that are even better in terms of
efficacy and safety than CQ, then we could use the advantages of quinoline antimalarial drugs in another attempt at
eradicating the disease. Given the RCQ potencies, it is conceivable to aim for single-dose radical cures that are hoped
for in an elimination / eradication global strategy [52, 53],
especially as a part of combination drugs in which the partners are carefully chosen to complement each other’s abilities and properties.
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